Get the Stockscreener App
95.59
0.30%
-0.2459
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $95.59, with a volume of 2.71M.
It is down -0.30% in the last 24 hours and up +5.59% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$95.84
Open:
$95.11
24h Volume:
2.71M
Relative Volume:
0.21
Market Cap:
$166.45B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
26.63
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
+3.66%
1M Performance:
+5.59%
6M Performance:
-24.27%
1Y Performance:
-28.35%
1-Day Range:
$94.30
$96.19
1-Week Range:
$91.91
$98.14
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
95.56 | 166.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.55 | 126.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
82.30 | 107.31B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.75 | 67.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
94.18 | 54.60B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
FreeStyle Libre 3 Sensor from Abbott Laboratoriesdiscreet glucose tracking for active diabetes pa - AD HOC NEWS
Is Abbott Laboratories (ABT) Undervalued After Its Glucose Monitoring Growth Narrative? - simplywall.st
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom - The Motley Fool
Abbott (ABT) Has a Multi-Platform Device-and-Diagnostics Engine Bigger Than the Libre Narrative - AlphaStreet
Trump Admin Stopped Criminal Charges Against Abbott Nutrition for Infant Formula Illnesses - Food Safety Magazine
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Abbott Laboratories (ABT) Stock Analysis: A Healthcare Giant with a 22.35% Upside Potential - DirectorsTalk Interviews
DOJ Closing Abbott Labs Case Spurs Wider Corporate Crime Retreat - Bloomberg Law News
Abbott Laboratories Stock (ABT) Opinions on Recent FDA Approvals and Product Launches - Quiver Quantitative
ABT Stock Quote Price and Forecast - CNN
Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering - Seeking Alpha
Abbott Laboratories (NYSE:ABT) Passes the Caviar Cruise Quality Screen with Strong Growth and Profitability - ChartMill
Is Index Shuffle And Probe Shift Reshaping The Investment Case For Abbott Laboratories (ABT)? - simplywall.st
DOJ ends investigation into infant formula company linked to deadly cronobacter outbreak - foodsafetynews.com
Abbott Laboratories (ABT) Shares Surge 3.5% -- What GF Score of 80 Tells Investors - GuruFocus
Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula - Reuters
Trump Loaded Up on Abbott Laboratories Stock Before His DOJ Dropped Criminal Probe - Common Dreams
A Mom Said Infant Formula Killed Her Baby. The Manufacturer Closed the File. - KFF Health News
Abbott Laboratories (NYSE: ABT) director receives 432 stock equivalent units as deferred fees - Stock Titan
Abbott Laboratories (ABT) director granted 416 stock equivalent units as board fees - Stock Titan
Abbott (ABT) director receives 363 stock equivalent units as board compensation - Stock Titan
Abbott (ABT) director Kevin Conroy receives 231 stock equivalent units as fees - Stock Titan
Form 4 Abbott Laboratories For: 1 July By Investing.com - Investing.com Canada
Abbott Laboratories (ABT) director receives 347 stock equivalent units as board compensation - Stock Titan
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott (NYSE: ABT) EVP withholds 269 shares to satisfy tax obligations - Stock Titan
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott (ABT) Clears A Major Legal Risk As DOJ Ends Criminal Formula Probe - Yahoo Finance
Has Abbott Laboratories (ABT) Fallen Too Far Below Fair Value? - simplywall.st
Baird starts Abbott at Outperform, sees product pipeline driving growth - Yahoo Finance
Baird starts Abbott at Outperform, sees product pipeline driving growth By Investing.com - Investing.com Canada
Abbott Laboratories (ABT) Receives Outperform Rating from Baird with $121 Target - GuruFocus
Abbott Laboratories highlights diversified healthcare portfolio as a long-term driver - AD HOC NEWS
Abbott gains as Baird issues new outperform on growth outlook - MSN
Abbott stock gains as Baird issues new Outperform (ABT:NYSE) - Seeking Alpha
Baird initiates Abbott stock coverage with Outperform rating - Investing.com
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX, and More - 24/7 Wall St.
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
US criminal probe into Abbott infant-formula plant closed - Global Food Industry News
Abbott Laboratories earnings calendar, shares in focus on the NYSE - AD HOC NEWS
Abbott Laboratories was investigated for poisoning babies. After a $500,000 donation, Trump let them off the hook. - More Perfect Union | Substack
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo! Finance Canada
Form 4 Abbott Laboratories For: 29 June By Investing.com - Investing.com Canada
Abbott (ABT) EVP Cushman disposes 560 shares for tax withholding, retains 38,013 - Stock Titan
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Coca Cola Stock And 2 Defensive Picks For Steady Dividends - simplywall.st
MDL Sought for Abbott Spinal Cord Stimulator Lawsuits - AboutLawsuits.com
Price to sales forward of Abbott Laboratories Pakistan Limited – PSX:ABOT - TradingView
How Abbott's Largest Segment Is Preparing for the Next Growth Phase - TradingView
Abbott Laboratories dropped from Russell Top 50, shares hold above Tradegate level - AD HOC NEWS
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):